FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321781496> ?p ?o ?g. }

• W4321781496 endingPage "e31" @default.
• W4321781496 startingPage "e30" @default.
• W4321781496 abstract "We thank Dr. Urbanska for raising important points related to our study findings. We agree that the treatment of ALK-positive (ALK+) NSCLC is challenging and that it is important to further characterize optimal treatments for refractory ALK+ NSCLC on the basis of relevant biomarkers. Factors contributing to the complexity in identifying optimal treatments include the rarity of ALK+ NSCLC and difficulties in obtaining rebiopsy samples in patients who progress after first-line therapy. We also agree that the findings from ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) do not address the molecular characterization of patients who respond to brigatinib in the second-line setting, because such characterization would have required patients to be enrolled on the basis of rebiopsy results after they progressed from first-line therapy. Characterization of the molecular determinants of clinical outcomes with brigatinib was an exploratory end point of ALTA-2. In ALTA-2, 100 of 103 total patients had baseline circulating tumor DNA (ctDNA) samples and 48 patients had end-of-treatment samples. Our clinical study team made great efforts working with the sites to collect tumor samples, but only five tumor samples were collected from patients who underwent rebiopsy after first-line therapy. Mutations detected in patients with ALK+ NSCLC who receive prior therapy are heterogenous, 1 Kang J. Chen H.J. Zhang X.C. et al. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. Thorac Cancer. 2018; 9: 1093-1103 Crossref PubMed Scopus (17) Google Scholar , 2 Lin Y.T. Chiang C.L. Hung J.Y. et al. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. Eur J Cancer. 2021; 156: 1-11 Abstract Full Text Full Text PDF PubMed Scopus (21) Google Scholar , 3 Pailler E. Faugeroux V. Oulhen M. et al. Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non-small-cell lung cancer. Clin Cancer Res. 2019; 25: 6671-6682 Crossref PubMed Scopus (76) Google Scholar making it challenging to accrue an adequate number of samples to assess therapies in patients with specific baseline co-mutations in the second-line setting and beyond. Among ongoing biomarker-driven studies in patients with ALK+ NSCLC, the estimated time from study start to completion ranges from approximately 4 years to more than 7 years, underscoring the challenges in recruitment of this patient population. The design of clinical studies in patients with ALK+ NSCLC must be balanced between the feasibility of enrollment of patients with specific mutations and speed to obtain the answer to a clinical question. Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?Journal of Thoracic OncologyVol. 18Issue 3PreviewWe read with great interest the article by Ou et al.1 regarding the ALTA-2 study evaluating brigatinib in patients with advanced ALK-positive NSCLC and disease progression during alectinib or ceritinib treatment. The authors reported data from 103 patients receiving brigatinib as second (35 patients) or later-line (68 patients) with corresponding objective response rates of 20% and approximately 30%, respectively. The independent review committee's objective response rate for the whole group was 26.2%, and the median progression-free survival was 3.8 months. Full-Text PDF" @default.
• W4321781496 created "2023-02-25" @default.
• W4321781496 creator A5067386747 @default.
• W4321781496 creator A5087923582 @default.
• W4321781496 date "2023-03-01" @default.
• W4321781496 modified "2023-09-27" @default.
• W4321781496 title "Response to: Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?" @default.
• W4321781496 cites W2861076589 @default.
• W4321781496 cites W2969664042 @default.
• W4321781496 cites W3109531772 @default.
• W4321781496 cites W3195755339 @default.
• W4321781496 cites W4295297459 @default.
• W4321781496 doi "https://doi.org/10.1016/j.jtho.2023.01.004" @default.
• W4321781496 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36842818" @default.
• W4321781496 hasPublicationYear "2023" @default.
• W4321781496 type Work @default.
• W4321781496 citedByCount "0" @default.
• W4321781496 crossrefType "journal-article" @default.
• W4321781496 hasAuthorship W4321781496A5067386747 @default.
• W4321781496 hasAuthorship W4321781496A5087923582 @default.
• W4321781496 hasConcept C117643217 @default.
• W4321781496 hasConcept C121608353 @default.
• W4321781496 hasConcept C126322002 @default.
• W4321781496 hasConcept C143998085 @default.
• W4321781496 hasConcept C203092338 @default.
• W4321781496 hasConcept C2776232967 @default.
• W4321781496 hasConcept C2776256026 @default.
• W4321781496 hasConcept C2777626846 @default.
• W4321781496 hasConcept C2778087573 @default.
• W4321781496 hasConcept C2778347629 @default.
• W4321781496 hasConcept C2779220645 @default.
• W4321781496 hasConcept C2779422266 @default.
• W4321781496 hasConcept C2779438470 @default.
• W4321781496 hasConcept C2779750558 @default.
• W4321781496 hasConcept C2908647359 @default.
• W4321781496 hasConcept C535046627 @default.
• W4321781496 hasConcept C71924100 @default.
• W4321781496 hasConcept C99454951 @default.
• W4321781496 hasConceptScore W4321781496C117643217 @default.
• W4321781496 hasConceptScore W4321781496C121608353 @default.
• W4321781496 hasConceptScore W4321781496C126322002 @default.
• W4321781496 hasConceptScore W4321781496C143998085 @default.
• W4321781496 hasConceptScore W4321781496C203092338 @default.
• W4321781496 hasConceptScore W4321781496C2776232967 @default.
• W4321781496 hasConceptScore W4321781496C2776256026 @default.
• W4321781496 hasConceptScore W4321781496C2777626846 @default.
• W4321781496 hasConceptScore W4321781496C2778087573 @default.
• W4321781496 hasConceptScore W4321781496C2778347629 @default.
• W4321781496 hasConceptScore W4321781496C2779220645 @default.
• W4321781496 hasConceptScore W4321781496C2779422266 @default.
• W4321781496 hasConceptScore W4321781496C2779438470 @default.
• W4321781496 hasConceptScore W4321781496C2779750558 @default.
• W4321781496 hasConceptScore W4321781496C2908647359 @default.
• W4321781496 hasConceptScore W4321781496C535046627 @default.
• W4321781496 hasConceptScore W4321781496C71924100 @default.
• W4321781496 hasConceptScore W4321781496C99454951 @default.
• W4321781496 hasIssue "3" @default.
• W4321781496 hasLocation W43217814961 @default.
• W4321781496 hasLocation W43217814962 @default.
• W4321781496 hasOpenAccess W4321781496 @default.
• W4321781496 hasPrimaryLocation W43217814961 @default.
• W4321781496 hasRelatedWork W2252065383 @default.
• W4321781496 hasRelatedWork W2299266038 @default.
• W4321781496 hasRelatedWork W2488914293 @default.
• W4321781496 hasRelatedWork W2503069423 @default.
• W4321781496 hasRelatedWork W2570575076 @default.
• W4321781496 hasRelatedWork W2624310346 @default.
• W4321781496 hasRelatedWork W2773891005 @default.
• W4321781496 hasRelatedWork W2811131358 @default.
• W4321781496 hasRelatedWork W4226461380 @default.
• W4321781496 hasRelatedWork W4321781496 @default.
• W4321781496 hasVolume "18" @default.
• W4321781496 isParatext "false" @default.
• W4321781496 isRetracted "false" @default.
• W4321781496 workType "article" @default.